Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma
Plain-language summary
This trial is testing Linperlisib in combination with CHOP for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Linperlisib in combination with CHOP (DRUG): Patients will receive six cycles of induction therapy of linperlisib in combination with CHOP regimen. All patients with CR and PR after induction therapy receive linperlisib maintenance therapy every 28 days until disease progression or other reasons lead to discontinuation, and the duration of linperlisib maintenance does not exceed 24 months.
Linperlisib in combination with CHOP
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details